Specificity and 6-month durability of immune responses induced by DNA and recombinant modified vaccinia ankara vaccines expressing HIV-1 virus-like particles

Journal of Infectious Diseases

Volumn 210, Issue 1, 2014, Pages 99-110

  Goepfert, Paul A ^a   Elizaga, Marnie L ^b   Seaton, Kelly ^d   Tomaras, Georgia D ^d   Montefiori, David C ^d   Sato, Alicia ^b   Hural, John ^b   DeRosa, Stephen C ^b,c   Kalams, Spyros A ^e   McElrath, M Juliana ^b,c   Keefer, Michael C ^f   Baden, Lindsey R ⁱ   Lama, Javier R ^o   Sanchez, Jorge ^o   Mulligan, Mark J ^j   Buchbinder, Susan P ^l   Hammer, Scott M ^g   Koblin, Beryl A ^h   Pensiero, Michael ^m   Butler, Chris ^m   Moss, Bernard ⁿ   Robinson, Harriet L ^k   Donastorg, Yeycy ^p   Qin, Li ^p   Lawrence, Dale ^p   Cardinali, Massimo ^p   Bae, Jin ^p   Holt, Renée ^p   Redinger, Huguette ^p   Johannessen, Jan ^p   Broder, Gail ^p   Moody White, Jerri ^p   McKay, Butch ^p   Calazans, Gabriela ^p   Bentley, Carter ^p   Kakinami, Lisa ^p   Skibinski, Katie ^p   Estep, Scharla ^p   Tseng, Jenny ^p   Swenson, Molly ^p   Madenwald, Tamra ^p   Overton, Edgar Turner ^p   Edupuganti, Srilatha ^p   Rouphael, Nadine ^p   Whitaker, Jennifer ^p   Hay, C Mhorag ^p   Bunce, Catherine A ^p   Gonzales, Pedro ^p   Hurtado, Juan Carlos ^p   Dolin, Raphael ^p   Mayer, Ken ^p   Walsh, Steven ^p   Johnson, Jennifer ^p   more..

^a UNIVERSITY OF ALABAMA SCHOOL OF MEDICINE   (United States)

^b Fred Hutchinson Cancer Research Center   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

^d DUKE UNIVERSITY MEDICAL CENTER   (United States)

^e VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

^g Och Spine at New York Presbyterian Hospitals   (United States)

^h NEW YORK BLOOD CENTER   (United States)

ⁱ HARVARD MEDICAL SCHOOL   (United States)

^j EMORY UNIVERSITY   (United States)

^k Research and Development   (United States)

^l SAN FRANCISCO DEPARTMENT OF PUBLIC HEALTH   (United States)

^m Division of AIDS   (United States)

ⁿ NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^o ASOCIACIÓN CIVIL IMPACTA SALUD Y EDUCACIÓN   (Peru)

^p NONE

more..

Author keywords

Antibodies; Clinical trial; DNA; HIV AIDS; Recombinant MVA; T cells; Vaccines

Indexed keywords

DNA VACCINE; GAG PROTEIN; GAMMA INTERFERON; GEOVAX VACCINE; GLYCOPROTEIN GP 120; GLYCOPROTEIN GP 41; GRANZYME B; IMMUNOGLOBULIN ANTIBODY; INTERLEUKIN 2; MODIFIED VACCINIA VIRUS ANKARA VACCINE; POL PROTEIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VIRUS ENVELOPE PROTEIN; VIRUS VACCINE;

ABSENCE OF SIDE EFFECTS; ADULT; ALLERGIC REACTION; ANTIBODY RESPONSE; ANTIBODY SPECIFICITY; ANTIBODY TITER; ANTIGEN BINDING; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DOUBLE BLIND PROCEDURE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IMMUNOGENICITY; INJECTION SITE PAIN; MAJOR CLINICAL STUDY; MALE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; VACCINATION; VACCINIA VIRUS; VIRUS PARTICLE;

ANTIBODIES; CLINICAL TRIAL; DNA; HIV/AIDS; RECOMBINANT MVA; T CELLS; VACCINES;

ADOLESCENT; ADULT; AIDS VACCINES; DRUG CARRIERS; ENV GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; FEMALE; HIV ANTIBODIES; HIV-1; HUMANS; MALE; MIDDLE AGED; PLACEBOS; T-LYMPHOCYTES; TIME FACTORS; VACCINES, SYNTHETIC; VACCINES, VIRUS-LIKE PARTICLE; VACCINIA VIRUS; YOUNG ADULT;

EID: 84904296964     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jiu003     Document Type: Article

References (45)

1. Haynes BF, Kelsoe G, Harrison SC, Kepler TB. B-cell-lineage immunogen design in vaccine development with HIV-1 as a case study. Nat Biotechnol 2012; 30:423-33.
2. Robinson HL. Non-neutralizing antibodies in prevention of HIV infection. Expert Opin Biol Ther 2013; 13:197-207.
3. Ackerman ME, Dugast AS, Alter G. Emerging concepts on the role of innate immunity in the prevention and control of HIV infection. Annu Rev Med 2012; 63:113-30.
4. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med 2009; 361:2209-20.
5. Pitisuttithum P, Gilbert P, Gurwith M, et al. Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand. J Infect Dis 2006; 194:1661-71.
6. Montefiori DC, Karnasuta C, Huang Y, et al. Magnitude and breadth of the neutralizing antibody response in the RV144 and Vax003 HIV-1 vaccine efficacy trials. J Infect Dis 2012; 206:431-41.
7. Haynes BF, Gilbert PB, McElrath MJ, et al. Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N Engl J Med 2012; 366:1275-86.
8. Zolla-Pazner S, deCamp AC, Cardozo T, et al. Analysis of V2 antibody responses induced in vaccinees in the ALVAC/AIDSVAX HIV-1 vaccine efficacy trial. PLoS One 2013; 8:e53629.
9. Liao HX, Bonsignori M, Alam SM, et al. Vaccine induction of antibodies against a structurally heterogeneous site of immune pressure within HIV-1 envelope protein variable regions 1 and 2. Immunity 2013; 38:176-86.
10. Bonsignori M, Pollara J, Moody MA, et al. Antibody-dependent cellular cytotoxicity-mediating antibodies from an HIV-1 vaccine efficacy trial target multiple epitopes and preferentially use the VH1 gene family. J Virol 2012; 86:11521-32.
11. Tomaras GD, Ferrari G, Shen X, et al. Vaccine-induced plasma IgA specific for the C1 region of the HIV-1 envelope blocks binding and effector function of IgG. Proc Natl Acad Sci U S A 2013; 110:9019-24.
12. Liu P, Yates NL, Shen X, et al. Infectious virion capture by HIV-1 gp120-specific IgG from RV144 vaccinees. J Virol 2013; 87:7828-36.
13. Karasavvas N, Billings E, Rao M, et al. The Thai Phase III HIV Type 1 Vaccine trial (RV144) regimen induces antibodies that target conserved regions within the V2 loop of gp120. AIDS Res Hum Retroviruses 2012; 28:1444-57.
14. Robb ML, Rerks-Ngarm S, Nitayaphan S, et al. Risk behaviour and time as covariates for efficacy of the HIV vaccine regimen ALVAC-HIV (vCP1521) and AIDSVAX B/E: a post-hoc analysis of the Thai phase 3 efficacy trial RV 144. Lancet Infect Dis 2012; 12:531-7.
15. Smith JM, Amara RR, McClure HM, et al. Multiprotein HIV-1 Clade B DNA/MVA Vaccine: Construction, Safety and Immunogenicity. AIDS Res Hum Retroviruses 2004; 20:654-65.
16. Smith JM, Amara RR, Campbell D, et al. DNA/MVA vaccine for HIV type 1: effects of codon-optimization and the expression of aggregates or virus-like particles on the immunogenicity of the DNA prime. AIDS Res Hum Retroviruses 2004; 20:1335-47.
17. Wyatt LS, Earl PL, Liu JY, et al. Multiprotein HIV type 1 clade B DNA and MVA vaccines: construction, expression, and immunogenicity in rodents of the MVA component. AIDS Res Hum Retroviruses 2004; 20:645-53.
18. Lai L, Kwa S, Kozlowski PA, et al. Prevention of infection by a granulocyte- macrophage colony-stimualting factor co-expressing DNA/modified vaccinia Ankara simian immunodeficiency virus vaccine. J Infect Dis 2011; 204:164-73.
19. Goepfert PA, Elizaga ML, Sato A, et al. Phase 1 safety and immunogenicity testing of DNA and recombinant modified vaccinia Ankara vaccines expressing HIV-1 virus-like particles. J Infect Dis 2011; 203:610-9.
20. Lai L, Kwa SF, Kozlowski PA, et al. SIVmac239 MVA vaccine with and without a DNA prime, similar prevention of infection by a repeated dose SIVsmE660 challenge despite different immune responses. Vaccine 2012; 30:1737-45.
21. Wyatt LS, Belyakov IM, Earl PL, Berzofsky JA, Moss B. Enhanced cell surface expression, immunogenicity and genetic stability resulting from a spontaneous truncation of HIV Env expressed by a recombinant MVA. Virology 2008; 372:260-72.
22. Tomaras GD, Yates NL, Liu P, et al. Initial B-cell responses to transmitted human immunodeficiency virus type 1: virion-binding immunoglobulin M (IgM) and IgG antibodies followed by plasma anti-gp41 antibodies with ineffective control of initial viremia. J Virol 2008; 82:12449-63.
23. Cooper CJ, Metch B, Dragavon J, Coombs RW, Baden LR, Force NHVTNV-IST. Vaccine-induced HIV seropositivity/reactivity in noninfected HIV vaccine recipients. JAMA 2010; 304:275-83.
24. Bolard G, Prior JO, Modolo L, et al. Performance comparison of two commercial BGO-based PET/CT scanners using NEMA NU 2-2001. Med Phys 2007; 34:2708-17.
25. Bull M, Lee D, Stucky J, et al. Defining blood processing parameters for optimal detection of cryopreserved antigen-specific responses for HIV vaccine trials. J Immunol Methods 2007; 322:57-69.
26. Horton H, Thomas EP, Stucky JA, et al. Optimization and validation of an 8-color intracellular cytokine staining (ICS) assay to quantify antigenspecific T cells induced by vaccination. J Immunol Methods 2007; 323:39-54.
27. McElrath MJ, De Rosa SC, Moodie Z, et al. HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case-cohort analysis. Lancet 2008; 372:1894-905.
28. Li F, Malhotra U, Gilbert PB, et al. Peptide selection for human immunodeficiency virus type 1 CTL-based vaccine evaluation. Vaccine 2006; 24:6893-904.
29. Agresti C, Bernardo A, Del Russo N, et al. Synergistic stimulation of MHC class I and IRF-1 gene expression by IFN-gamma and TNFalpha in oligodendrocytes. Eur J Neurosci 1998; 10:2975-83.
30. Goepfert PA, Tomaras GD, Horton H, et al. Durable HIV-1 antibody and T-cell responses elicited by an adjuvanted multi-protein recombinant vaccine in uninfected human volunteers. Vaccine 2007; 25:510-8.
31. Pulendran B, Ahmed R. Translating innate immunity into immunological memory: implications for vaccine development. Cell 2006; 124: 849-63.
32. Slifka MK, Antia R, Whitmire JK, Ahmed R. Humoral immunity due to long-lived plasma cells. Immunity 1998; 8:363-72.
33. Yates NL, Stacey AR, Nolen TL, et al. HIV-1 gp41 envelope IgA is frequently elicited after transmission but has an initial short response halflife. Mucosal Immunol 2013; 6:692-703.
34. Burton DR, Hessell AJ, Keele BF, et al. Limited or no protection by weakly or nonneutralizing antibodies against vaginal SHIV challenge of macaques compared with a strongly neutralizing antibody. Proc Natl Acad Sci U S A 2011; 108:11181-6.
35. Finnegan CM, Berg W, Lewis GK, DeVico AL. Antigenic properties of the human immunodeficiency virus transmembrane glycoprotein during cell-cell fusion. J Virol 2002; 76:12123-34.
36. Edwards TG, Wyss S, Reeves JD, et al. Truncation of the cytoplasmic domain induces exposure of conserved regions in the ectodomain of human immunodeficiency virus type 1 envelope protein. J Virol 2002; 76:2683-91.
37. Buchbinder SP, Mehrotra DV, Duerr A, et al. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a doubleblind, randomised, placebo-controlled, test-of-concept trial. Lancet 2008; 372:1881-93.
38. Cohen J. AIDS research. More woes for struggling HIV vaccine field. Science 2013; 340:667.
39. Paris RM, Kim JH, Robb ML, Michael NL. Prime-boost immunization with poxvirus or adenovirus vectors as a strategy to develop a protective vaccine for HIV-1. Expert Rev Vaccines 2010; 9:1055-69.
40. Keefer MC, Frey SE, Elizaga M, et al. A phase I trial of preventive HIV vaccination with heterologous poxviral-vectors containing matching HIV-1 inserts in healthy HIV-uninfected subjects. Vaccine 2011; 29:1948-58.
41. Churchyard GJ, Morgan C, Adams E, et al. A phase IIA randomized clinical trial of a multiclade HIV-1 DNA prime followed by a multiclade rAd5 HIV-1 vaccine boost in healthy adults (HVTN204). PLoS One 2011; 6:e21225.
42. Edwards BH, Bansal A, Sabbaj S, Bakari J, Mulligan MJ, Goepfert PA. Magnitude of functional CD8+ T-cell responses to the gag protein of human immunodeficiency virus type 1 correlates inversely with viral load in plasma. J Virol 2002; 76:2298-305.
43. Nqoko B, Day CL, Mansoor N, et al. HIV-specific gag responses in early infancy correlate with clinical outcome and inversely with viral load. AIDS Res Hum Retroviruses 2011; 27:1311-6.
44. Perez CL, Milush JM, Buggert M, et al. Targeting of conserved gagepitopes in early HIV infection is associated with lower plasma viral load and slower CD4(+) T cell depletion. AIDS Res Hum Retroviruses 2013; 29:602-12.
45. Kiepiela P, Ngumbela K, Thobakgale C, et al. CD8+ T-cell responses to different HIV proteins have discordant associations with viral load. Nat Med 2007; 13:46-53.